drugset
drugset / Trial / NCT03241264

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

NCT03241264 ↗

Phase 1 Completed 12 enrolled Bristol-Myers Squibb Nitto Denko Corporation · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and the effects two ND-L02-s0201 have on the body

Timeline

Start
2016-08-28
Primary completion
2016-10-21
Completion
2016-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ND-L02-s0201 Small interfering RNA (siRNA) — Intravenous

Indications

No indication recorded.